Barrett oesophagus.
View / Open Files
Authors
Peters, Yonne
Al-Kaabi, Ali
Shaheen, Nicholas J
Chak, Amitabh
Blum, Andrew
Souza, Rhonda F
Iyer, Prasad G
Pech, Oliver
Siersema, Peter D
Journal Title
Nature Reviews Disease Primers
ISSN
2056-676X
Publisher
Springer Nature
Volume
5
Issue
1
Pages
35-35
Language
eng
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Peters, Y., Al-Kaabi, A., Shaheen, N. J., Chak, A., Blum, A., Souza, R. F., Di Pietro, M., et al. (2019). Barrett oesophagus.. Nature Reviews Disease Primers, 5 (1), 35-35. https://doi.org/10.1038/s41572-019-0086-z
Abstract
Barrett oesophagus (BE), the only known histological precursor of oesophageal adenocarcinoma (EAC), is a condition in which the squamous epithelium of the oesophagus is replaced by columnar epithelium as an adaptive response to gastro-oesophageal reflux. EAC has one of the fastest rising incidences of cancers in Western countries and has a dismal prognosis. BE is usually detected during endoscopic examination, and diagnosis is confirmed by the histological presence of intestinal metaplasia. Advances in genomics and transcriptomics have improved our understanding of the pathogenesis and malignant progression of intestinal metaplasia. As the majority of EAC cases are diagnosed in individuals without a known history of BE, screening for BE could potentially decrease disease-related mortality. Owing to the pre-malignant nature of BE, endoscopic surveillance of patients with BE is imperative for early detection and treatment of dysplasia to prevent further progression to invasive EAC. Developments in endoscopic therapy have resulted in a major shift in the treatment of patients with BE who have dysplasia or early EAC, from surgical resection to endoscopic resection and ablation. In addition to symptom control by optimization of lifestyle and pharmacological therapy with proton pump inhibitors, chemopreventive strategies based on NSAIDs and statins are currently being investigated for BE management.
Keywords
Barrett Esophagus, Disease Progression, Gastroesophageal Reflux, Humans, Life Style, Mass Screening, Prognosis, Risk Factors
Identifiers
External DOI: https://doi.org/10.1038/s41572-019-0086-z
This record's URL: https://www.repository.cam.ac.uk/handle/1810/298666
Rights
All rights reserved